|
|
|
|
|
|
|
 |
You are here : Home > People & Partners The management team
Chris Moyses MRCP, FPPM, DM - Non-Executive Chairman. Chris obtained his BA in Physiological Sciences at Oxford and his MB/BChir at Cambridge University. He became a member of the Royal College of Physicians in 1983 and obtained his DM at Oxford three years later and became an FFPM in 1999. Chris worked for Searle and ICI before becoming Vice President of Clinical and Regulatory Affairs at Amylin. He was then Chief Medical Officer and Development Director of Oxford GlycoSciences plc (OGS) and, as a Board Director of OGS, had firsthand involvement in raising £170 million as a secondary offering in 2000. On leaving OGS, Chris was a Non-Executive Director of KetoCytonyx Inc., R&D Director of Pharmagene plc and, latterly, Chief Medical Officer of Argenta Discovery. Currently, Chris is also a non-executive director of Ardana plc in addition to his role with Senexis.
David Paxton, FCCA - Company Secretary and Financial Controller. David Paxton is a Certified Accountant, having qualified in 1966. He has been self-employed for 12 years working as a part-time Management Accountant for a variety of small to medium-sized companies. David previously gained wide experience in commerce where he was the Financial Director of a small division of a PLC based in Coventry. He has also worked in private practice with firms of Solicitors, Surveyors, Estate Agents and Chartered Accountants, including Pannell Kerr Forster in Birmingham and Worcester where he was partnership secretary. David has recently focused on working with a number of early-stage Life Science Companies. |
J Mark Treherne BSc, MPhil, PhD,
MIoD - Chief Executive. Mark obtained his PhD in receptor neuropharmacology from Cambridge University
with funding from Merck. He then went on to complete a post-doc on diabetes, before holding a Senior Faculty position at the Biozentrum
in Basel. Mark now has over 20 year's experience in the discovery of
novel treatments for diseases of the central and peripheral nervous
systems, including Parkinson's and Alzheimer's diseases. Mark was
formerly at Pfizer in the UK, where he was responsible for
research into neurodegenerative diseases. On leaving Pfizer in 1997,
Mark set up Cambridge Drug Discovery as Chief Executive, which was sold to BioFocus
in 2001 for £28 million. Mark has now been involved in raising over £50 million for various early-stage biotechnology companies.
David Scopes, BSc, MSc, PhD - Chief Scientific Officer. David obtained his BSc, MSc and
Ph.D. in Chemistry from the University of Manchester. This was
followed by periods of postdoctoral research at Syntex Corporation in Palo Alto and at the University of Illinois,
Urbana-Champaign. David joined Glaxo in 1976 and became a Research Manager in the UK,
focussing on central nervous system disorders, before running a department of chemists as Head of Medicinal Chemistry at GlaxoWellcome in France. David joined Oxford GlycoSciences in 1996 as Director of Chemistry, later becoming Vice-President of Drug Discovery and joined Senexis in 2004.